Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity by Klein, J-L D et al.
A primary strategy of cancer chemotherapy is to administer cyto-
toxic drugs to destroy malignant tumour cells at doses that do not
compromise the function of healthy tissues critical for the survival
of the patient. Unfortunately, the structural or behavioural differ-
ences between normal and malignant cells are not absolute so that
the selectivity of cytotoxic agents is relative. Epithelial linings,
such as the oropharynx and the gastrointestinal tract, and the bone
marrow are among the most sensitive tissues (Dorr and Fritz,
1980; Hoagland, 1992; Perry, 1992; Pratt et al, 1994). In fact,
myelosuppression is often the dose-limiting feature in
chemotherapy regimens for a number of diseases, including cancer
(Hoagland, 1992) and acquired immune deficiency syndrome
(AIDS) (Richman et al, 1987; Shaunak and Bartlett, 1989; Walker
et al, 1987; McLeod and Hammer, 1992). Supporting patients
through a period of myelosuppression or decreased resistance to
infection has become a significant part of a chemotherapeutic
regimen (Vose and Armitage, 1992).
Several strategies have been deployed in recent years to over-
come the side-effects of chemotherapy with much of the attention
focused on stimulation of the haematopoietic system.
Haematopoietic cytokines, such as interleukin-2, granulocyte
colony-stimulating factor (G-CSF), granulocyte–macrophage
colony-stimulating factor (GM-CSF), and erythropoietin (Epo)
have been used to stimulate recovery of bone marrow function in
patients receiving chemotherapy (Fischl et al, 1990; Davey et al,
1991; Laporte et al, 1991; Aviles et al, 1995) with G-CSF yielding
the most clinical utility so far (for example, see Donadieu et al,
1997 and Gisselbrecht et al, 1997). Unfortunately, these
haematopoietic growth factors have significant side-effects at stan-
dard doses and provide only limited protection. For example,
approximately 30% of AIDS patients who receive 3¢-azido-3¢-
deoxythymidine (AZT) in combination with haematopoietic
growth factors still require blood transfusions partly due to the
drug-induced myelosuppression (Miles, 1992). Recent studies with
negative haematopoietic regulatory factors, such as macrophage
inflammatory protein-1a (Lord et al, 1992; Hunter et al, 1995) and
the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Aidoudi et al, 1996;
Watanabe et al, 1996), have shown promise as important haemo-
protective agents during chemotherapy. However, additional clin-
ical trials with these agents are needed to confirm their utility.
Earlier studies in our laboratory suggested that swainsonine, a
protein glycosylation inhibitor known to block metastasis in
experimental systems, may be effective in stimulating bone
marrow recovery with less severe side-effects than G-CSF or GM-
CSF (Oredipe et al, 1991). However, two important issues remain
to be addressed. First, do the protective effects of swainsonine
administration limit the effectiveness of cytoreductive chemother-
apeutic drugs? Second, although studies in mouse model systems
are important in elaborating the functional potential of swainso-
nine as a hematopoietic growth factor, the relevance of the data to
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Research Triangle Park, NC 27709, USAclinical application has not yet been established. If the mouse data
are confirmed with human bone marrow, swainsonine may offer
promise in future intensive chemotherapy programmes, allowing
increased dosage and/or frequency of administration of cytotoxic
agents without increasing toxic effects to the haematopoietic
system.
We report here that swainsonine does not reduce the effective-
ness of cytoreductive chemotherapeutic drugs and that swainso-
nine has protective effects on certain classes of both murine and
human blood cells.
MATERIALS AND METHODS
Materials
Preparations of swainsonine used in these studies were chemically
synthesized by and purchased from Toronto Research Chemicals,
Inc. (North York, Ontario, Canada). Interleukin-3 and Epo were
obtained from R&D Systems (Minneapolis, MN, USA) and
reconstituted according to the manufacturer’s directions. AZT was
synthesized by Raylo Chemical Co. (Edmonton, Alberta, Canada)
and obtained through the Chemistry Support Group at NIEHS.
Cyclophosphamide, purchased as Cytoxan® for injection (Bristol
Myers, Princeton, NJ, USA), was freshly prepared before use by
dissolving the powder in sterile non-pyrogenic 0.9% sodium
chloride solution to yield a 1 mg ml–1 solution, as recommended
by the supplier.
Animals
Pathogen-free female C57BL/6 mice, 7–9 weeks old, were
obtained from Charles River Laboratories, Raleigh, NC, USA, and
similar female B6C3F1 mice were obtained from the National
Cancer Institute Animal Program, Bethesda, MD, USA. Mice
were allowed at least 1 week to acclimate prior to experimentation
and were fed a standard diet in a humidity- and temperature-
controlled room. The animals were handled according to institu-
tional ethical guidelines.
B16-F1 cell culture
B16-F1 murine melanoma cells (Dr IJ Fidler, The University of
Texas MD Anderson Cancer Center, Houston, TX, USA) were
grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco
BRL, Life Technologies, Grand Island, NY, USA) supplemented
with 5% Fetal Clone II (HyClone Laboratories, Inc., Logan, UT,
USA), sodium pyruvate (1 mM), non-essential amino acids
(0.1 mM), MEM vitamin solution (1 X), L-glutamine (2 mM), peni-
cillin (50 IU ml–1) and streptomycin (50 mg ml–1). Cells were
grown as monolayers in tissue culture flasks in a humidified
atmosphere of 5% CO2–95% air at 37°C. Cells to be used for inoc-
ulation were removed from flasks by treatment with 0.25% trypsin
in 0.02% EDTA and were washed twice with Ca2+Mg2+-free phos-
phate-buffered saline solution (PBS) before injection into mice.
Cell plating efficiency
Cells were plated at 200 cells per each 60 mm dish in DMEM
supplemented with 5% fetal bovine serum, L-glutamine (2 mM),
penicillin (100 IU ml–1) and streptomycin (100 mg ml–1). Cyclo-
phosphamide (0, 0.1, 0.5, 0.75, 1 or 2 mM) and swainsonine (0, 3,
10 or 50 mgm l –1) were added to the medium just prior to
addition of the cells. Cells were grown as described above for
8 days, washed once with PBS, fixed 15 min in methanol, air
dried, stained with 4% Giemsa stain, air dried and scored. A
cluster of 15 or more cells was counted as a colony. Five plates
were used for each point.
Generation of experimental tumours in C57BL/6 mice
Mice were inoculated subcutaneously in the upper back with
5 ´ 104 viable B16-F1 melanoma cells in 0.2 ml of sterile non-
pyrogenic 0.9% sodium chloride solution. Animals developed
palpable tumours within 12–14 days. Mice were injected intraperi-
toneally (i.p.) with swainsonine (3 mg) or saline twice daily for 10
consecutive days beginning 1 day prior to the administration of
cyclophosphamide, that is, day –1 when a single dose of
cyclophosphamide was given and days –1 and 13 when two doses
of cyclophosphamide were given. Cyclophosphamide-treated
mice received a single i.p. injection of cyclophosphamide
(500 mg kg–1 body weight) on day 0 only, or on day 0 and day 14.
Animals bearing tumours were euthanized when appropriate
according to NIEHS guidelines. Tumours were measured every
2–3 days with a caliper (Biomedical Research Instruments,
Rockville, MD, USA). Tumour volumes were calculated using the
formula: V = 4/3 p (r1
2 ´ r2) where r1 and r2 are the minor and
major radii respectively.
Murine bone marrow cellularity
Bone marrow cell suspensions were prepared under sterile condi-
tions using both femora and tibiae from each mouse. Tissue was
removed aseptically from bones, the ends were opened, and the
bone marrow cells were flushed from the marrow cavities with a
sterile syringe and a 26-gauge needle with 10 ml of ice-cold
RPMI-1640 medium (Gibco BRL) supplemented with 3% bovine
serum albumin (BSA; Sigma, St Louis, MO, USA). Cells were
then collected by centrifugation and resuspended in 10 ml of ice-
cold RPMI. Single cell suspensions were obtained by initially
passing cell suspensions through a 22-gauge needle, then again
through a 25-gauge needle. The remaining cell clusters were elim-
inated by filtering the cell suspensions through a 70 mm nylon
mesh (Falcon, Franklin Lakes, NJ, USA). Cells were counted with
a Coulter Counter ZM (Coulter Corp., Miami, FL, USA). Numbers
are reported as total nucleated bone marrow cells per two posterior
legs (two femora and two tibiae).
Mouse bone marrow progenitor cell assay
Bone marrow progenitor cells were grown using either the Mouse
Bone Marrow Stem Cell Differentiation kit from Gibco BRL
or the MethoCultTM M3330 or M3230 media from StemCell
Technologies, Inc. (Vancouver, BC, Canada). For the Mouse Bone
Marrow Stem Cell Differentiation kit, Epo (2 U) and interleukin-3
(75 U) were added to the 0.75 ml progenitor cell growth medium
containing methylcellulose. Mononuclear bone marrow cells
(0.25 ml at 0.5 ´ 106 cells per ml) were then added, mixed by
vortexing, and aliquoted (0.5 ml per well) into a 24-well tissue
culture dish. The cells were incubated for 14 days in a humidified
incubator at 37°C and 5% carbon dioxide.
The MethoCultTM M3330 medium contains fetal bovine serum
(30%) and Epo (10 ng ml–1). This medium is designed for the
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bone marrow. The MethoCultTM M3230 contains 30% fetal bovine
serum and does not contain any added growth factors; it is
designed for the growth of murine granulocyte–macrophage prog-
enitor cells (GM-CFC). For either medium, 0.1 ml of bone marrow
cells (at 2 ´ 106 or 5.6 ´ 105 cells per ml for M3330 or M3230
respectively) was added to 0.9 ml of the prepared methylcellulose
medium. The cells and medium were then mixed with a vortex,
transferred to a 35-mm dish and placed in a humidified incubator
at 37°C and 5% carbon dioxide. Early E-CFC were scored after
2 days of incubation; GM-CFC were scored after 7 days.
According to the manufacturer’s instructions, 200–300 early
E-CFC should be present when 2 ´ 105 nucleated bone marrow
cells are plated in M3330 medium. With the M3230 medium, 5–20
GM-CFC colonies are typically scored when 5.6 ´ 104 nucleated
bone marrow cells are plated.
AZT and swainsonine treatment
Groups of 10 B6C3F1 female mice received AZT dissolved in
methylcellulose, administered by oral gavage twice daily (400 mg
AZT per kg body weight per day, total dose). Swainsonine,
dissolved in sterile saline, was administered by i.p. injection twice
daily (1 mg kg–1 body weight total daily dose, 0.2 ml per injection)
beginning on the same day as AZT treatment and continuing until
the animal was sacrificed. Blood samples were obtained from the
retro-orbital sinuses of animals anaesthetized with isoflurane and
dioxygen. Complete blood counts and white blood cell differential
counts were generated using the Technicon H*1 haematology
analyser (Miles, Inc., Tarrytown, NY, USA). Wright–Giemsa
stained smears and spun microhaematocrits were prepared for each
sample. Reticulocyte counts were obtained from blood smears
stained with new methylene blue. White blood cell differential
counts were performed with a light microscope on at least two
samples from each group for comparison with the automated
counts and for evaluating cell morphology. All H*1 differential
counts that were determined to be abnormal were confirmed by
manual counts using the prepared smears.
Human bone marrow progenitor cell assay
Human bone marrow samples were obtained either on the occasion
of a bone marrow allograft by aspiration from the iliac crest of a
healthy donor or from a patient in complete remission after a
haematological disease. Cells (5 ´ 104 mononuclear human bone
marrow cells) were plated in complete methylcellulose medium
(MethoCultTM H4433, StemCell Technologies, Inc.) in the pres-
ence or absence of AZT or swainsonine. Colonies were identified
and scored with an inverted microscope after 14 days incubation at
37°C and 5% carbon dioxide in a humidified atmosphere as
described (Calenda et al, 1992a, 1992b, 1993). Each sample was
plated in triplicate.
The isobologram analysis, described by Elion et al (1954),
was used to test for the antagonistic or synergistic behaviour of
compounds administered simultaneously. In the experiments with
human bone marrow progenitor cells, we tested various concentra-
tions of AZT (0.1, 1, 10 and 100 mM) in combination with various
concentrations of swainsonine (1, 10, 50 and 100 mg ml–1). This
experimental design generates a series of growth curves for each
concentration of AZT associated with a concentration of swain-
sonine. Fractional inhibitory concentrations (FIC) for AZT and
swainsonine were then calculated by dividing the concentration of
the first compound present in the combination by the amount of
the second drug, which is required to give 95% inhibition of cell
growth. The FICs of pairs of drugs were then plotted and
compared to the line connecting unity on the ordinate to unity on
the abscissa. This line represents a strictly additive effect of the
two compounds. Points above and to the right of this line indicate
antagonism between two drugs, whereas points below and to the
left of this line represent synergism.
Leukaemia and lymphoma cell lines
The human leukaemia cell lines HL-60 and Jurkat were obtained
from the ATCC (Rockville, MD, USA) and were grown in RPMI-
1640 medium (Gibco BRL) supplemented with 20% Fetal Clone
II, L-glutamine (2 mM), penicillin (100 IU ml–1) and streptomycin
(100 mg ml–1). WEHI 3B, a mouse leukaemia cell line was the kind
gift of Dr A R Migliaccio (New York Blood Center, New York,
NY, USA) and was cultured in RPMI medium, supplemented with
10% Fetal Clone II, L-glutamine (2 mM), penicillin (100 IU ml–1)
and streptomycin (100 mg ml–1). WR19L, a mouse lymphoma cell
line was obtained from ATCC and was grown in DMEM supple-
mented with 10% Fetal Clone II, L-glutamine (2 mM), penicillin
(100 IU ml–1) and streptomycin (100 mg ml–1). All cell lines were
tested and found to be negative for mycoplasma.
For the methylcellulose assay, cells were plated either in
‘complete’ methylcellulose medium MethoCultTM M3434
(StemCell Technologies, Inc.) which contains 0.9% methylcellu-
lose in Iscove’s MDM, 15% fetal bovine serum, BSA (1%), bovine
pancreatic insulin (10 mg ml–1), human transferrin (200 mg ml–1),
2-mercaptoethanol (0.1 mM),  L-glutamine (2 mM), recombinant
murine interleukin-3 (10 ng ml–1), recombinant human interleukin-
6 (10 ng ml–1), recombinant murine stem cell factor (50 ng ml–1)
and recombinant human Epo (3 units per ml), or in MethoCultTM
M3230 (also from StemCell Technologies, Inc.) which contains
0.9% methylcellulose in a-MEM, fetal bovine serum (30%),
BSA (1%), 2-mercaptoethanol (0.1 mM) and glutamine (2 mM).
Colonies consisting of more than 30 cells were scored 7–14 days
later, depending on the cell line.
Statistics
Tumour sizes in mice were compared using an analysis of variance
on the log-transformed volumes of the subcutaneous mass. In
other experiments, P-values were calculated using either Student’s
two-tailed paired t-test or Student’s one-tailed paired t-test, as
appropriate.
RESULTS
Tumour cell killing capacity of cyclophosphamide in
presence of swainsonine
B16-F1 cells were chosen as the tumour model to see whether
swainsonine influenced the cytotoxicity of cyclophosphamide
either in vitro or in vivo. To examine the effects of swainsonine
on cyclophosphamide toxicity in vitro, the plating efficiency of
B16-F1 cells was examined by co-exposing cells to cyclophos-
phamide and swainsonine, to cyclophosphamide plus the swainso-
nine buffer, or to swainsonine plus the cyclophosphamide buffer.
The dose of cyclophosphamide used in this experiment (750 mM)
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up to 2.5 mM were tested; 750 mM cyclophosphamide-treated B16-
F1 melanoma cells gave rise to a plating efficiency approximately
one-half that of the control (Table 1). The addition of swainsonine
had no effect on the plating efficiency of the cells in the absence of
cyclophosphamide at any of the concentrations tested (Table 1).
This is consistent with previous findings that swainsonine does not
interfere with cell growth in vitro (Humphries et al, 1986). In the
presence of a cyclophosphamide dose that significantly reduced
plating efficiency of the tumour cells, swainsonine appeared to
cause a very slight decrease in the number of colonies (Table 1).
These results indicate that swainsonine does not interfere with the
cytotoxicity of cyclophosphamide in vitro.
To determine whether swainsonine alters the toxicity of
cyclophosphamide in vivo, mice bearing palpable tumours (ten
mice per group) were exposed to both agents using a clinically-
relevant regimen. On day zero, animals were given a single i.p.
injection of cyclophosphamide (500 mg per kg body weight) or
solvent buffer (saline). The i.p. administration of swainsonine
(3 mg in 0.2 ml saline) was initiated 1 day prior (day –1) to injec-
tion of cyclophosphamide and was continued at a frequency of two
injections per day for 10 consecutive days. Tumours grew rapidly
in animals that received either saline or swainsonine alone (Figure
1) and tumours in the two groups were similar in size. However,
tumours in mice that received cyclophosphamide (Figure 1)
remained small and relatively constant in size for about 2 weeks
after injection of cyclophosphamide. Tumours in mice that
received both cyclophosphamide and swainsonine were slightly
larger than those in the cyclophosphamide-treated mice (see
Figure 1A, day 9), primarily due to the required euthanasia on day
9 of several mice in the cyclophosphamide group which had the
largest tumours (the euthanasia was necessitated by NIEHS
criteria for morbidity, including weight loss, tumour ulceration and
prolonged unhealthy appearance). An analysis of variance of the
log-transformed tumour volumes indicated that the inhibition
of tumour size by cyclophosphamide was highly significant
(P < 0.001), that swainsonine alone had no effect on tumour
size and that, in the presence of swainsonine, cyclophosphamide
continued to have highly significant inhibitory effect on tumour
growth (P < 0.001).
Because there was an increase in tumour size in both the
cyclophosphamide and cyclophosphamide plus swainsonine
groups after day 14, another experiment was performed in which a
second dose of cyclophosphamide, with or without swainsonine,
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Table 1 Effect of swainsonine and cyclophosphamide on the plating
efficiency of B16-F1 murine melanoma cells
Swainsonine
Plating efficiency (%)
Cyclophosphamide
0 mM 750 mM
0 mg ml–1 32 ± 4 18 ± 2
3 mg ml–1 31 ± 4 13 ± 1
10 mg ml–1 29 ± 5 15 ± 3
50 mg ml–1 32 ± 2 14 ± 3
B16-F1 murine melanoma cells were plated at 200 cells per dish as
described in Materials and Methods. After 8 days, colonies of 15 cells or
more were scored. Five plates were used for each variable. Numbers are the
means ± standard deviation.
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Figure 1 Effect of swainsonine on anti-tumour activity of cyclophosphamide on C57BL/6 mice. (A) Melanoma-bearing C57BL/6 mice were injected i.p. twice
daily with swainsonine (3 mg per injection) or saline (as a control) starting on day –1 and continuing for 10 consecutive days. Cyclophosphamide (500 mg kg–1
body weight) was administered to two groups of ten animals as a single injection on day 0. One group of ten cyclophosphamide-treated animals also received a
10-day course of swainsonine. Tumours were measured every 2–3 days. Each line represents the mean tumour size from a group of ten mice. Error bars
represent the standard errors. Statistical analysis indicated that there was no difference in tumour sizes between saline- and swainsonine-treated animals, a
highly significant decrease in tumour size in the cyclophosphamide-treated group (P < 0.001), a highly significant decrease in the tumour size of
cyclophosphamide with swainsonine-treated mice (P < 0.001) and a slight difference between cyclophosphamide and cyclophosphamide with swainsonine-
treated groups (P < 0.05). (B) Melanoma-bearing C57BL/6 mice were treated as in A, except that a second dose of cyclophosphamide (500  mg kg–1 body
weight) was given at day 14 to the surviving mice from the two groups that initially received cyclophosphamide at day 0. Animals that initially received both
cyclophosphamide and swainsonine were also given an additional course of swainsonine (10 days, twice daily i.p. injections of 3 mg swainsonine per injection)
starting at day 13. Error bars represent the standard errors. In this experiment, there was no difference between saline- and swainsonine-treated animals, a
significant decrease in tumour size in both the cyclophosphamide- and cyclophosphamide with swainsonine-treated animals (P < 0.01), and no difference
between the cyclophosphamide- and cyclophosphamide with swainsonine-treated groups (P > 0.05)was given at day 14 to the surviving mice (Figure 1B). As before,
the cyclophosphamide-treated animals had much smaller tumours
than mice treated with saline or swainsonine alone during the first
course of treatment (P < 0.01). (None of the saline- or swainso-
nine-treated animals survived to day 14, and thus, were not candi-
dates for the second dose.) The data showed that a second round of
chemotherapy extended the time during which the growth of the
B16-F1-derived tumours was inhibited (Figure 1B). Furthermore,
administration of swainsonine for 10 days during the second round
of cyclophosphamide treatment had no effect on the reduction in
growth of the tumours from days 14 to 31. These results indicated
that swainsonine did not compromise the therapeutic index of
cyclophosphamide, allowing the anti-tumour drug to slow tumour
growth through at least two cycles of therapy. Taken together with
the in vitro results, this demonstrates that swainsonine does not
interfere with the antineoplastic activity of cyclophosphamide
toward B16-F1 melanoma tumour cells.
During the course of these experiments, we noted the days
following treatment on which animals had to be euthanized due to
NIEHS guidelines regarding either tumour size, overall weight
loss, or general morbidity. All tumour-bearing animals given
saline alone or swainsonine alone had to be euthanized within
17 days of the initiation of treatment in the first experiment
(Figure 1A) and within 10 days in the second experiment (Figure
1B). On the other hand, only 33% of tumour-bearing animals that
received cyclophosphamide had to be euthanized during this same
period, and this number was reduced to 20% when swainsonine
was co-administered with cyclophosphamide. This observation is
consistent with previously published studies (Oredipe et al, 1991)
that showed swainsonine reduced the toxicity of cyclophos-
phamide in non-tumour-bearing mice.
Effect of swainsonine on the haematopoietic toxicity of
AZT
Prior studies have examined the effects of swainsonine on four
chemical agents used in the treatment of cancer; therefore, we
considered whether swainsonine is effective in protecting the bone
marrow against myelosuppressive agents used in the treatment of
AIDS. We focused on AZT because it is one of the most
commonly used drugs in the treatment of AIDS and because its
limiting toxicity is haematopoietic (Yarchoan et al, 1989; McLeod
and Hammer, 1992).
We used the mouse model in these studies because it has been
reported that female B6C3F1 mice that received AZT twice a day
by oral gavage developed myelosuppression (Thompson et al,
1991). In our study, AZT was administered by gavage for 23
consecutive days; control animals received methylcellulose
without AZT and i.p. injection of saline instead of swainsonine.
AZT treatment resulted in a significant decrease in bone marrow
cellularity after 15 days (39 ± 4 ´ 106 cells in two posterior legs vs
57 ± 5 ´ 106 cells in two posterior legs for treated and control
animals respectively). Similar results were obtained after 23 days
of treatment (Figure 2). Treatment of healthy animals with
swainsonine had no apparent effect on bone marrow cellularity.
However, co-treatment with AZT and swainsonine led to a signifi-
cant increase in bone marrow cellularity.
AZT-induced myelosuppression was also evident in peripheral
blood cell counts. Animals treated with AZT for as little as 5 days
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Table 2 Effect of swainsonine on haematological parameters in AZT-treated mice
WBC Lymphocytes Monocytes RBC HGB HCT MCV MCH MCHC Platelets Reticulocytes
Treatment (cells ml–1) (cells ml–1) (cells ml–1) (mil ml–1) (g dl–1) (%) (fl) (pg) (g dl–1) (1000 ml–1) (1000 ml–1)
Vehicles 4250± 340 3090± 310 130± 20 8.1± 0.1 13.1± 0.3 42.3± 0.5 52.0± 0.6 16.2± 0.4 31.1± 0.5 1080± 80 150± 30
AZT a2790 ± 180 a2300 ± 150 a33 ± 6 a5.4 ± 0.6 a10 ± 1 a31 ± 4 a57± 1 a18.4 ± 0.3 a32.2 ± 0.4 a1680 ± 80 a49 ± 27
Sw 4110 ± 460 3130 ± 380 110± 10 a8.8 ± 0.1 a14.6 ± 0.1 a46.2 ± 0.4 52.4 ± 0.4 16.6 ± 0.1 31.7 ± 0.3 1120 ± 80 a100 ± 20
AZT/Sw b4360 ± 580 b3820 ± 540 a55 ± 10 a5.4 ± 0.7 a10 ± 1.5 a32 ± 5 a57 ± 2 a18.4 ± 0.5 32.0 ± 0.5 a1900 ± 100 a30 ± 13
Animals were treated with AZT (400 mg kg–1 body weight) twice daily by oral gavage and with swainsonine (Sw, 1 mg kg–1 body weight) twice daily by i.p
injection as described in the Materials and Methods. Animals were bled on day 23 and cells were counted and identified by the Technicon H*1 haematology
analyser and Wright–Giemsa stained smears. Each number represents the means ± standard error of 6–10 animals. Abbreviations: WBC, total leucocytes;
RBC, erythrocytes; HGB, haemoglobin; HCT, haematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular
haemoglobin concentration. aSignificantly different from vehicle control value, P < 0.05. bSignificantly different from AZT-treated value, P < 0.05.
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Figure 2 Effect of swainsonine on bone marrow cellularity of AZT-treated
B6C3F1 mice. AZT (400 mg kg–1 body weight per day) was dissolved in
methylcellulose and given by oral gavage in two equal doses per day.
Swainsonine (0.2 ml per injection, 1 mg kg–1 body weight per day) was
injected i.p. twice a day with the first dose administered immediately following
the administration of the AZT. Twenty-three days after the beginning of the
treatment, three animals per group were sacrificed and the bone marrow
cells from both femora and tibiae were flushed out and counted. Numbers
given are the mean nucleated cells per two femora and two tibiae. The
difference between AZT-treated mice and the control group was statistically
significant (P < 0.05 using one-tailed t-test, used because previous data have
shown that AZT treatment reduces bone marrow cellularity); the increase in
cellularity due to swainsonine was also statistically significant (P < 0.01 for
AZT alone vs AZT plus swainsonine using a two-tailed t-test).displayed reduced peripheral red blood cells (RBC), haematocrit,
reticulocytes, monocytes and eosinophils (data not shown). The
results of an experiment involving 23 days of AZT treatment are
shown in Table 2. Swainsonine treatment alone caused a slight, but
statistically significant, increase in RBC count and haematocrit,
and a slight decrease in reticulocytes. However, swainsonine treat-
ment of mice that received AZT for 23 consecutive days markedly
increased the number of white blood cells compared to animals
treated with AZT alone. This effect was essentially due to a large
increase in the number of lymphocytes in AZT-treated animals that
received swainsonine (Table 2).
Swainsonine effect on the growth of murine bone
marrow progenitor cells in culture
To determine whether swainsonine directly affected bone marrow
progenitor cells, short-term haematopoietic cultures were used.
The addition of swainsonine to the growth medium significantly
increased the number of early murine E-CFC (230% of control),
with the optimum stimulation at a concentration of 3 mg ml–1
(Figure 3). Similarly, swainsonine increased the number of GM-
CFC with a maximum increase (210%) at concentrations between
0.03 and 10 mg ml–1.
To examine the ability of swainsonine to alter the toxicity of
AZT toward bone marrow cells, both agents were added to the
culture medium. The results, shown in Figure 4, indicate that AZT
decreased the number of both erythroid and myeloid colonies in
methylcellulose cultures. For example, 0.5 mM AZT inhibited
growth of GM-CFC by about 80%. Erythroid colonies were more
sensitive to AZT toxicity, as 0.5 mM AZT completely inhibited
E-CFC growth. However, swainsonine protected both myeloid and
erythroid progenitor cells from the toxicity of AZT. For example,
addition of swainsonine (1 mgm l –1) to the medium containing
0.5 mM AZT restored the number of murine GM-CFC to a level
similar to the control (Figure 4A).
Swainsonine effects on human bone marrow
progenitor cells treated with AZT in vitro
We next examined the effects of swainsonine on human bone
marrow progenitor cells in vitro. In the presence of AZT, swainso-
nine induced a 20–30% increase in the number of human GM-
CFC over that observed with AZT alone in the culture medium
(Table 3). This effect was observed for two different concentra-
tions of swainsonine and in bone marrow cultures from four
different donors. Further analysis of these results using the
isobologram method (Elion et al, 1954) clearly showed that swain-
sonine antagonized the toxicity of AZT on human bone marrow
cells in vitro in the two bone marrow samples which yielded data
amenable to this analysis (Figure 5). The protection of human
bone marrow progenitor cells was similar to that observed with
murine bone marrow cells. These results demonstrated that swain-
sonine reduced the toxicity of a known myelosuppressive drug on
human myeloid progenitor cells.
Swainsonine effects on haematopoietic cell lines in vitro
Any clinical utility of swainsonine will depend in part on its ability
to stimulate haematopoietic cells without harmful side-effects.
One potential side-effect, based on the observed stimulation of
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Figure 3 Effect of swainsonine on murine bone marrow colony-forming
units. Bone marrow cells from C57BL/6 mice were isolated and cultured in
methylcellulose as described. Swainsonine was added to the methylcellulose
medium at the concentrations indicated on the graph. For early E-CFC,
3 ´ 105 nucleated bone marrow cells were plated in M3330 medium and
incubated for 2 days, at which time erythroid colonies were identified and
scored. Data are expressed as a percentage of the control and are the
average of three experiments (except for 0.3 and 30 mg ml–1 of swainsonine,
which are each the average of two experiments). For GM-CFC, 5.6 ´ 104
bone marrow cells were plated in M3230 medium and incubated for 7 days,
at which time GM-CFC colonies were identified and scored. Each value is
the average of three plates and is expressed as a percentage of the control.
Bars represent the standard error
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Figure 4 Effect of swainsonine on murine bone marrow progenitor cell
growth in methylcellulose medium in the presence of AZT. AZT alone (n n) or
with 1 mg ml–1 of swainsonine (n) was added to the methylcellulose medium
at concentrations indicated on the graphs. After 14 days of incubation, CFC
were identified and scored. (A) GM-CFC; (B) early E-CFCnormal haematopoietic cells, is the stimulation of haematopoietic
tumour cells. Thus, we measured the effect of swainsonine on
several haematopoietic cell lines both in liquid culture and in
methylcellulose. Both human (Jurkat and HL-60) and murine
(WR19L and WEHI) haematopoietic cell lines were grown in the
presence and absence of swainsonine. None of the cell lines
showed any change in growth rate or cell number at saturation in
liquid culture (data not shown). Neither the WR19L, WEHI nor
HL-60 cells showed any change in colony-forming ability in
methylcellulose in a medium rich in growth factors. WEHI cells,
but not WR19L or HL-60 cells, displayed a two- to three-fold
increase in colony forming ability in methylcellulose cultures, but
only when the usual growth factors were omitted from the
medium. Thus, there does not appear to be any general stimulatory
effect of swainsonine for transformed cells of haematopoietic
origin.
DISCUSSION
In this report, we have shown that swainsonine protects both
murine and human bone marrow against the toxicity of drugs used
in the treatment of cancer and AIDS. These effects were shown in
the survival of tumour-bearing animals and haematopoietic cell
colony-forming ability following treatment with the clinically-
relevant drugs, cyclophosphamide and AZT. Significantly,
swainsonine did not block the tumour-killing capacity of
cyclophosphamide as monitored by in vitro plating efficiency and
inhibition of growth of subcutaneous xenografts of B16-F1 murine
melanoma. Swainsonine also antagonized the toxicity of AZT on
human bone marrow progenitor cells under conditions that did not
stimulate growth of murine or human haematopoietic tumour cells
in vitro. These studies represent the first demonstration that swain-
sonine can be used in combination with a cytotoxic anticancer
agent without diminishing the anti-tumour capacity of the drug.
Interestingly, swainsonine did not stimulate the number of
murine bone marrow cells in vivo when administered alone.
Rather, swainsonine appeared to improve the recovery of bone
marrow after haematological injuries (Oredipe et al, 1991). This
may be an important aspect of swainsonine’s activity, in that
highly stimulatory growth factors may actually sensitize bone
marrow progenitor cells to genotoxic damage by anti-tumor thera-
pies, which could ultimately lead to increased rates of leukaemia.
The mechanism by which swainsonine enhances survival is not
entirely clear. The fact that both melanoma cells in vitro and as a
tumour mass in vivo are sensitive to cyclophosphamide in the
presence of swainsonine suggests that swainsonine does not acti-
vate a general cellular detoxification pathway or block drug trans-
port into tumour cells. The one clear biochemical effect of
swainsonine (Elbein et al, 1981; Tulsiani et al, 1982; Tulsiani and
Touster, 1983; Olden et al, 1991) is the inhibition of a-mannosi-
dase activity in lysosomes and Golgi apparatus. The resulting
changes in protein glycosylation might lead to altered activity of
cell-surface receptors. This idea is consistent with the activity of
swainsonine observed in in vitro assays. The assay conditions used
for growth of the haematopoietic progenitors included the addition
of cytokines or a high percentage of bovine fetal serum that is rich
in growth factors. However, it has not yet been shown that swain-
sonine-altered glycosylation in haematopoietic progenitor cells
changes the cell’s response to cytokines. Further research on the
effects of glycosylation inhibitors on progenitor cells is clearly
needed.
In vitro swainsonine stimulated both erythroid and myeloid
murine progenitor cells. The absence of any strict lineage speci-
ficity indicated that swainsonine affects multiple cell types and,
therefore, should not lead to the risk of lineage diversion observed
with treatments of certain highly specific cytokines (Miles, 1992).
This mild stimulatory effect of swainsonine compensates for the
toxicity of AZT toward murine bone marrow progenitor cells in
vitro. At a concentration of AZT that yields an 80% reduction in
GM-CFC, swainsonine restored the number of colonies to a level
similar to that observed in the control cultures.
Although the weight adjusted dose of AZT given to mice in
these experiments is higher than that used in typical therapy for
AIDS patients (1500 mg per patient daily), the dose is only about
50% higher than AZT levels given to humans in high-dose regi-
mens, using an equivalent surface area dose (Zaretsky, 1995). Our
results suggest that high doses of AZT may be clinically feasible,
given the ability of swainsonine to prevent some aspects of the
myelosuppression associated with AZT treatment.
Swainsonine-treated murine haematopoietic cells did not
become completely insensitive to AZT toxicity, suggesting that
swainsonine does not induce resistance to toxicity of AZT as does
interleukin-1 (Abraham et al, 1993). In this sense, swainsonine
appears more similar to Epo or GM-CSF in that these cytokines
restore the cellularity of AZT-treated bone marrow without actu-
ally blocking cytotoxicity (Miles, 1992). The stimulation by
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Table 3 Effects of swainsonine (Sw) on human bone marrow colonies
growing in presence of AZT
Sw concentrations Average increase
over AZT alone
50 mg ml–1 19.4% ± 3.9
P < 0.01
100 mg ml–1 27.6% ± 5.1
P < 0.02
The values are the average of the percentage of the increase of the numbers
of GM-CFC colonies due to the addition of Sw in the medium containing 1 mM
AZT over the number of colonies from the medium containing AZT alone.
The P-values were calculated by Student’s two-tailed paired t-test.
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Figure 5 Isobologram analysis (Elion et al, 1954) of the effects of AZT and
swainsonine on human bone marrow colony-forming units. Fractional
inhibitory concentrations (FICs) were calculated by dividing the concentration
of the drug in the combination by the concentration of the drug alone required
to produce the selected inhibition of control growth (here 95%). The two stars
represent the relative FICs for AZT in the presence of swainsonine from the
two human GM-CFC data sets amenable to this analysisswainsonine of erythroid colonies in vitro correlated with the in
vivo observation on circulating red blood cells. Mice treated for 23
days with swainsonine showed a small but significant increase in
the number of RBC. However, this stimulation did not protect
RBCs from AZT toxicity. In contrast, swainsonine stimulated and
protected against AZT toxicity toward erythroid and myeloid
progenitor cells in vitro and led to an increase in lymphocytes in
the presence of AZT in vivo. As previously reported, murine
peripheral blood cells and their progenitors showed a similar
sensitivity to AZT (Cronkite and Bullis, 1990; Thompson et al,
1991). AZT treatment of mice for 23 days led to an almost 50%
decrease in white blood cell count compared to control animals.
When animals received swainsonine simultaneously with AZT, the
number of white blood cells was similar to the untreated control.
This protective effect was primarily due to the increased number
of lymphocytes in peripheral blood. A better understanding of the
mechanism by which swainsonine stimulates haematopoietic cells
may allow us to identify swainsonine-sensitive cell populations.
The stimulation of normal progenitor cells by swainsonine led
to concerns about the potential effect of swainsonine on
haematopoietic tumour cells. Our results show that only one of the
four haematopoietic tumour cell lines examined was stimulated by
swainsonine and, then, only under specific cell culture conditions
(in methylcellulose in the absence of added cytokines). From a
clinical perspective, these results suggest that swainsonine’s
activity on haematopoietic cells need not exclude its use in
patients with haematopoietic tumours.
This study provides critical information for the potential use of
swainsonine in the management of human malignancy. For swain-
sonine to be used in patients, it is desirable that swainsonine itself
be minimally toxic at effective doses. The toxicity of swainsonine
in patients with advanced malignancies has been recently exam-
ined (Goss et al, 1994). Patients received a continuous i.v. infusion
over 5 days with dose levels from 50 to 550 mg kg–1 day–1, levels
much higher than those used in our in vivo murine study based on
an equivalent surface area dose. Swainsonine caused significant
clinical toxicity only at the highest dose levels and only in patients
with abnormal pre-treatment liver function. These results suggest
that swainsonine may not be toxic at doses that yield significant
protection from high dose chemotherapy. Our data presented here,
combined with the clinical studies, suggest that swainsonine may
be a useful adjuvant in treatment protocols that use either high-
dose chemotherapy or multi-dose treatments in which myelosup-
pression is a major concern.
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